These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 37765153)

  • 1. Recent Advances and Innovations in the Preparation and Purification of In Vitro-Transcribed-mRNA-Based Molecules.
    Zhang J; Liu Y; Li C; Xiao Q; Zhang D; Chen Y; Rosenecker J; Ding X; Guan S
    Pharmaceutics; 2023 Aug; 15(9):. PubMed ID: 37765153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding the impact of
    Lenk R; Kleindienst W; Szabó GT; Baiersdörfer M; Boros G; Keller JM; Mahiny AJ; Vlatkovic I
    Front Mol Biosci; 2024; 11():1426129. PubMed ID: 39050733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advancements of in vitro transcribed mRNA (IVT mRNA) to enable translation into the clinics.
    Kang DD; Li H; Dong Y
    Adv Drug Deliv Rev; 2023 Aug; 199():114961. PubMed ID: 37321375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. mRNA vaccines: the most recent clinical applications of synthetic mRNA.
    Kwon S; Kwon M; Im S; Lee K; Lee H
    Arch Pharm Res; 2022 Apr; 45(4):245-262. PubMed ID: 35426547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Purification of linearized template plasmid DNA decreases double-stranded RNA formation during IVT reaction.
    Martínez J; Lampaya V; Larraga A; Magallón H; Casabona D
    Front Mol Biosci; 2023; 10():1248511. PubMed ID: 37842641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. mRNA-based therapies: Preclinical and clinical applications.
    Qureischi M; Mohr J; Arellano-Viera E; Knudsen SE; Vohidov F; Garitano-Trojaola A
    Int Rev Cell Mol Biol; 2022; 372():1-54. PubMed ID: 36064262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IVT-mRNA reprogramming of myeloid cells for cancer immunotherapy.
    Jolly KJ; Zhang F
    Adv Pharmacol; 2024; 100():247-288. PubMed ID: 39034054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An overview of rational design of mRNA-based therapeutics and vaccines.
    To KKW; Cho WCS
    Expert Opin Drug Discov; 2021 Nov; 16(11):1307-1317. PubMed ID: 34058918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mesoporous Silica Particle as an RNA Adsorbent for Facile Purification of In Vitro-Transcribed RNA.
    Cho E; Namgung J; Lee JS; Jang J; Jun BH; Kim DE
    Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Facile Method for the Removal of dsRNA Contaminant from In Vitro-Transcribed mRNA.
    Baiersdörfer M; Boros G; Muramatsu H; Mahiny A; Vlatkovic I; Sahin U; Karikó K
    Mol Ther Nucleic Acids; 2019 Apr; 15():26-35. PubMed ID: 30933724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Capillary electrophoresis methods for determining the IVT mRNA critical quality attributes of size and purity.
    Warzak DA; Pike WA; Luttgeharm KD
    SLAS Technol; 2023 Oct; 28(5):369-374. PubMed ID: 37833008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recruiting In Vitro Transcribed mRNA against Cancer Immunotherapy: A Contemporary Appraisal of the Current Landscape.
    Miliotou AN; Georgiou-Siafis SK; Ntenti C; Pappas IS; Papadopoulou LC
    Curr Issues Mol Biol; 2023 Nov; 45(11):9181-9214. PubMed ID: 37998753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Messenger RNA chromatographic purification: advances and challenges.
    Feng X; Su Z; Cheng Y; Ma G; Zhang S
    J Chromatogr A; 2023 Sep; 1707():464321. PubMed ID: 37639849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concise Review: Application of In Vitro Transcribed Messenger RNA for Cellular Engineering and Reprogramming: Progress and Challenges.
    Steinle H; Behring A; Schlensak C; Wendel HP; Avci-Adali M
    Stem Cells; 2017 Jan; 35(1):68-79. PubMed ID: 27250673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emergence of synthetic mRNA: In vitro synthesis of mRNA and its applications in regenerative medicine.
    Kwon H; Kim M; Seo Y; Moon YS; Lee HJ; Lee K; Lee H
    Biomaterials; 2018 Feb; 156():172-193. PubMed ID: 29197748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. mRNA technology as one of the promising platforms for the SARS-CoV-2 vaccine development.
    Ilyichev AA; Orlova LA; Sharabrin SV; Karpenko LI
    Vavilovskii Zhurnal Genet Selektsii; 2020 Nov; 24(7):802-807. PubMed ID: 33959697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ACE mRNA (Additional Chimeric Element incorporated IVT mRNA) for Enhancing Protein Expression by Modulating Immunogenicity.
    Son S; Park M; Kim J; Lee K
    Adv Sci (Weinh); 2024 May; 11(18):e2307541. PubMed ID: 38447169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems.
    Guan S; Rosenecker J
    Gene Ther; 2017 Mar; 24(3):133-143. PubMed ID: 28094775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anion exchange HPLC monitoring of mRNA
    Welbourne EN; Loveday KA; Nair A; Nourafkan E; Qu J; Cook K; Kis Z; Dickman MJ
    Front Mol Biosci; 2024; 11():1250833. PubMed ID: 38516194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. mRNA-Based Therapeutics in Cancer Treatment.
    Sun H; Zhang Y; Wang G; Yang W; Xu Y
    Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36839944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.